CG Oncology (CGON) EBT Margin (2023 - 2026)
CG Oncology's (CGON) quarterly EBT Margin came in at 40904.25% in Q1 2026, up 19326498.0% YoY from N/an in Q1 2025, and down 2217.93% on a QoQ basis from 1764.69% in Q4 2025.
Powered by 
Analysis
CG Oncology (CGON) EBT Margin (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of EBT Margin data on file, last reported at 40904.25% in Q1 2026.
- Quarterly EBT Margin rose 19326498.0% year-over-year to 40904.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17088.9% (up 5891760.0% YoY) and the FY2025 annual result came in at 8895.74%, up 832963.0% from the prior year.
- EBT Margin slipped to 40904.25% in Q1 2026, from 1764.69% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 1764.69% in Q4 2025 to a low of 1655100.0% in Q4 2023.
- A 4-year average of 245793.82% and a median of 46903.4% in 2024 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 164811228 bps in 2024, down 28167080 bps in 2024.
- Tracing CGON's EBT Margin over 4 years: stood at 1655100.0% in 2023, then jumped by 100 bps to 6987.72% in 2024, then surged by 75 bps to 1764.69% in 2025, then slumped by 2218 bps to 40904.25% in 2026.
- The last three EBT Margin figures came in at 40904.25% (Q1 2026), 1764.69% (Q4 2025), and 14071.67% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 12.09% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -2.67% |
| 10 | CG Oncology | 6.55 Bn | 6.55 Bn | -2.77 Mn | -6,834.23% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6,834.23% |
| Mar 31, 2026 | -5,549.49% |
| Dec 31, 2025 | -1,776.74% |
| Sep 30, 2025 | -2,623.53% |
| Mar 31, 2025 | -66,263.46% |
| Dec 31, 2024 | -6,974.56% |
| Sep 30, 2024 | -47,448.84% |
| Jun 30, 2024 | -17,036.04% |
| Mar 31, 2024 | -3,199.43% |
| Dec 31, 2023 | -1,655,100.00% |
| Sep 30, 2023 | -130,666.67% |
| Mar 31, 2023 | -4,471.65% |